The cancer diagnostics company Bibb Instruments intends to carry out a rights issue of approximately SEK 60 million before transaction costs, according to a press release.The terms of the issue, such as the subscription price, are expected to be announced on March 18. The subscription period is expected to run between March 30 and April 13.Ahead of the issue, Bibb has received subscription intentions and guarantee undertakings of up to approximately SEK 42 million, which means that around 70 percent of the issue is secured. The proceeds of the issue are primarily intended to be used to accelerate the commercial launch in the USA and Europe, strengthen distributor support, and fully finance the next major product expansion, Endodrill EBUS for lung cancer, through FDA 510(k) clearance, clinical pilot studies, and an introductory launch."We now want to carry out a public offering that broadens the shareholder base and finances Bibb during 2026-2027 and enables a number of value-creating activities, such as expanded commercialization in the USA, launch in Europe, development of a new product variant for lung cancer, and continued build-up of evidence through clinical studies", comments CEO Fredrik Lindblad.